Significance of the plasminogen activator inhibitor of placental type (PAI-2) in pregnancy

Seminars in Thrombosis and Hemostasis

Volumn 24, Issue 5, 1998, Pages 431-435

  Åstedt, Birger ^a   Lindoff, Claes ^a   Lecander, Ingegerd ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Fibrinolysis; PAI 2; Preeclampsia; Pregnancy; t PA; u PA

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 2; TISSUE PLASMINOGEN ACTIVATOR;

CONFERENCE PAPER; DISEASE ASSOCIATION; FEMALE; HEMOSTASIS; HUMAN; INTRAUTERINE GROWTH RETARDATION; PREECLAMPSIA; PREGNANCY; PREMATURE FETUS MEMBRANE RUPTURE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; TROPHOBLAST; UTERUS CONTRACTION;

EID: 0031728717     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996035     Document Type: Conference Paper

References (72)

1. Nilsson IM, Kullander S. Coagulation and fibrinolytic studies during pregnancy. Acta Obstet Gynaecol Scand 1967;46:273-285
2. Bonnar J, McNicol GP, Douglas AS. Fibrinolytic enzyme system and pregnancy. Br Med J 1969;3:387-389
3. Åstedt B. On fibrinolysis. In pregnancy, labour, puerperium and during treatment with sex hormones. Acta Obstet Gynaecol Scand 1972;51:1-24
4. Stirling Y, Woolf L, North WRS, Seghatchian MJ, Meade TW. Haemostasis in normal pregnancy. Thromb Haemostas 1984; 52:176-182
5. Ballenger V, Mombaerts P, Declerck PJ, Spitz B, van Assche FA, Collen D. Fibrinolytic response in venous occlusion and fibrin fragment D-Dimer levels in normal and complicated pregnancy. Thromb Haemostas 1987;58:1030-1032
6. Wright JG, Cooper P, Åstedt B, et al. Fibrinolysis during normal human pregnancy: Complex inter-relationships between plasma levels of tissue plasminogen activator and inhibitors and the euglobulin clot lysis time. Br J Haematol 1988;69:253-258
7. Malm J, Laurell M, Dahlbäck B. Changes in the plasma levels of vitamin K-dependent protein C and S and of C4b binding protein during pregnancy and oral contraception. Br J Haematol 1988;68:437-443
8. Gilabert I, Fernandez A, Espanà F, Aznar J, Estellés A. Physiological coagulation inhibitors (protein S, protein C and anti-thrombin III) in severe preeclamptic states and in users of oral contraceptives. Thromb Res 1988;49:319-320
9. Dahlbäck B. Protein S and C4b-binding protein: Components involved in the regulation of the protein C anticoagulant system. Thromb Haemostas 1991;66:49-61
10. Lecander I, Åstedt B. Isolation of anew specific plasminogen activator inhibitor from pregnancy plasma. Br J Haematol 1986;62:221-228
11. Kruithof EKO, Tran-Thang C, Gudinchet A, et al. Fibrinolysis in pregnancy: A study of plasminogen activator inhibitor. Blood 1987;69:460-466
12. Lecander I, Åstedt B. Occurrence of a specific plasminogen activator inhibitor of placental type. PAI-2, in men and non-pregnant women. Fibrinolysis 1989;3:27-30
13. Binder BR. Influence of urokinase on cell proliferation and invasion. Blood Coag Fibrinolysis 1990;1:717-720
14. Saxne T, Lecander I, Geborek P. Plasminogen activators and plasminogen activator inhibitors in synovial fluid. Difference between inflammatory joint disorders and osteoarthritis. J Rheumatol 1993;20:91-96
15. Estellés A, Gilabert J, Espanà F, Aznar J, Gómez-Lechón MJ. Fibrinolysis in preeclampsia. Fibrinolysis 1987;1:209-214
16. de Boer K, Lecander I, ten Cate JW, Borm JJJ, Treffers PE. Placental-type plasminogen activator inhibitor in preeclampsia. Am J Obstet Gynecol 1988;158:418-422
17. Estellés A, Gilabert J, Aznar J, Loskutoff DJ, Schleef RR. Changes in the plasma levels of type 1 and type 2 plasminogen activator inhibitors in normal pregnancy and in patients with severe preeclampsia. Blood 1989;74:1332-1338
18. Reith A, Booth NA, Moore NR, Chruickshank DJ, Bennett B. Plasminogen activator inhibitors (PAI-1 and PAI-2) in the normal pregnancies, preeclampsia and hydatidiform mole. Br J Obstet Gynaecol 1993;100:370-374
19. Åstedt B. The placenta and haemostatic balance. In: Redman CWG, Sargent IL, Starkey PM, eds. The Human Placenta: A Guide for Clinicians and Scientists. Oxford: Blackwell Scientific, 1993:291-309
20. Estellés A, Gilabert J, Keeton M, et al. Altered expression of plasminogen activator type 1 in placentas from pregnant women with preeclampsia and/or intrauterine fetal growth retardation. Blood 1994;84:143-150
21. Lindoff C, Åstedt B. Plasminogen activator of urokinase type and its inhibitor of placental type in hypertensive pregnancies and in intrauterine growth retardation: Possible markers of placental function. Am J Obstet Gynecol 1994;171:60-64
22. He S, Bremme K, Almqvist I, Blombäck M. Decrease in plasminogen activator inhibitor type PAI-2 related more to placental function and intrauterine fetal growth than to severity of preeclampsia. Hypertension in Pregnancy 1996;15:171-182
23. Kawano T, Uemura Y. Inhibition of tissue activator by urokinase inhibitor. Thromb Diathes Haemorrhag 1971;25:129-133
24. Åstedt B, Pandolfi M, Nilsson IM. Inhibitory effect of placenta on plasminogen activation in human organ culture. Proc Soc Exp Biol Med 1972;139:1421-1424
25. Åstedt B. Hägerstrand I, Lecander I. Cellular localization in placenta of placental type plasminogen activator inhibitor. Thromb Haemostas 1986;56:63-65
26. Golder JP, Stephens RW. Minactivin: A human monocyte product with specifically inactive urokinase-type plasminogen activators. Eur J Biochem 1983;136:517-522
27. Saksela O, Hovi T, Vaheri A. Urokinase-type plasminogen activator and its inhibitor secreted by cultured human monocyte-macrophages. J Cell Physiol 1985;122:125-132
28. Chapman Jr HA, Stone OL. Characterization of a macrophage-derived plasminogen-activator inhibitor. Biochem J 1985;230: 109-116
29. Wohlwend A, Belin D, Vassalli JD. Plasminogen activator-specific inhibitors produced by human monocytes/macrophages. J Exp Med 1987;165:320-339
30. Sundström C, Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer 1976;17:565-577
31. Kruithof EKO, Vassalli J-D, Schleuning W-D, Mattalioano RJ, Bachmann F. Purification and characterization of a plasminogen activator inhibitor from the hisliocytic lymphoma cell line U-937. J Biol Chem 1986;261:11207-11213
32. Genton C, Kruithof EKO, Schleuning W-D. Phorbol ester induces the biosynthesis of glycosylated and non-glycosylated plasminogen activator inhibitor 2 in high excess over urokinase-type plasminogen activator in human U-937 lymphoma cells. J Cell Biol 1987;104:705-712
33. Åstedt B, Lecander I, Brodin T, Lundblad A, Löw K. Purification of a specific placental plasminogen activator inhibitor by monoclonal antibody and its complex formation with plasminogen activator. Thromb Haemostas 1985;53:122-125
34. Asledt B, Lecander I, Ny T. The placental type plasminogen activator inhibitor, PAI-2. Fibrinolysis 1987;1:203-208
35. Kruithof EKO, Baker MS, Bunn CL. Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood 1995; 86:4007-4024
36. Lecander I, Roblin R, Åsledt B. Differential inhibition of two molecular forms of melanoma cell plasminogen activator by a placental inhibitor. Br J Haematol 1984;57:407-412
37. Åstedt B, Bladh B, Christensen U, Lecander I. Different inhibition of one and two chain tissue plasminogen activator by a placental inhibitor studied with two tripeplide p-nitroanilide substrates. Scan J Clin Lab Invest 1985;45:429-435
38. Wun T-C, Reich E. An inhibitor of plasminogen activation from human placenta. J Biol Chem 1987;262:3646-3653
39. Thorsen S, Philips M, Selmer J, Lecander I, Åsledt B. Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator hy plasminogen-activator inhibitor type 1 and type 2. Eur J Biochem 1988;175:33-39
40. Bohn H, Wickler W, Grundmann U. Immunochemically detected placental proteins and their biological functions. Arch Gynecol Obstet 1991;249:107-118
41. Lecander I, Åstedl B. Isolation of a new specific plasminogen activator inhibitor from pregnancy plasma. Br J Haematol 1986;62:221-228
42. Lecander I. Åstedt B. Specific plasminogen activator inhibitor of placental type occurring in amniotic fluid and cord blood. J Lab Clin Med 1987;110:602-605
43. Kruithof EKO, Tran-Thang C, Gudinehet A, et al. Fibrinolysis in pregnancy: A study of plasminogen activator inhibitors. Blood 1987;69:460-466
44. Jonasson A, Larsson B, Lecander I. Åstedt B. Placental and decidual u-PA, PAI-1 and PAI-2 concentrations, as affected by cervical dilatation with laminaria tents or Hegar dilators. Thromb Res 1989;54:91-97
45. Hofmann GE, Glatstein I, Schatz F, Heller D, Deligdisch L. Immunohistochemical localization of urokinase-type plasminogen activator and the plasminogen activator inhibitors 1 and 2 in early human implantation sites. Am J Obstet Gynecol 1994; 170:671-676
46. Zini JM, Murray SC, Graham CH, et al. Characterization of urokinase receptor expression by human placenlal trophoblasts. Blood 1992;79:2917-2929
47. Feinberg RF, Kao LC, Haimowitz JE, et al. Plasminogen activator inhibitor types 1 and 2 in human trophoblasts. PAI-1 is an immunocytochemical marker of invading trophoblasts. Lab Invest 1989;61:20-31
48. Ikeuchi M. The study of local fibrinolysis in abortion. Acta Obstet Gynaecol Jpn 1985;37:1215-1223
49. Svanberg L, Åstedt B, Nilsson IM. Abruptio placentae - treatment with the fibrinolytic inhibitor tranexamic acid. Acta Obstet Gynaecol Scand 1980;59:127-130
50. Koh CL, Viegas OA, Yuen R, Chua SE, Ng BL, Ratnam SS. Plasminogen activators and inhibitors in normal late pregnancy, postpartum and in the postnatal period. Int J Gynaecol Obstet 1992;38:9-18
51. Stegnar M, Zore A, Novak-Antolic Z, Vovk N, Kruithof EKO. Tissue-type plasminogen activator alter venous occlusion in pregnancy and puerperium. Thromb Haemostas 1993;70:486-490
52. Lindoff C, Lecander I, Åstedt B. Fibrinolytic components in individual consecutive plasma samples during normal pregnancy. Fibrinolysis 1993;7:190-194
53. Ästedt B. Demonstration of significance of placenta in depression of fibrinolytic activity during pregnancy. J Obstet Gynaecol Br Commonw 1972;79:205-206
54. Lecander I, Nilsson IM, Åstedt B. Depression of plasminogen activator activity during pregnancy by the placental inhibitor PA1-2. Fibrinolysis 1988;2:165-167
55. Juhan-Vague I, Moerman B, de Cock F, Ailland MF, Collen D. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb Res 1984;53:523-530
56. Nilsson IM, Ljungner H, Tengborn L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: Low concentration of plasminogen activator m increased concentration of plasminogen activator inhibitor. Br Med J 1985;290:1453-1456
57. Åstedt B, Bladh B, Christensen U, Lecander I. Different inhibition of one and two chain tissue plasminogen activator by a placental inhibitor studied with two tripeptide-p-nitroanilide substrates. Scand J Clin Lab Invest 1985;45:429-435
58. Kjaeldgaard A, Pschera H, Larsson B, Gaffney P, Åstedt B. Plasminogen activators and inhibitors in amniotic fluid. Fibrinolysis 1993;3:203-206
59. Jenkins DM, O'Neil M, Matter M, France VW, Hsi B-L, Faulk WP. Degenerative changes and detection of plasminogen in fetal membranes that rupture prematurely. Br J Obstet Gynaecol 1983;90:841-846
60. Evaldson GR, Larsson B. Is the fibrinolytic activity involved in the mechanism of fetal membrane rupture? A clinical study of term and prematurely ruptured membranes. Acta Obstet Gynaecol Scand 1987;66:315-317
61. Åstedt B, Lindoff C. Plasminogen activators and plasminogen activator inhibitors in plasma of premature and term newborns. Acta Paediatr 1997;86:111-113
62. Kinnby B, Mattsson L, Åstedt B. Aggravation of gingival inflammatory symptoms during pregnancy associated with the concentration of plasminogen activator inhibitor type 2 (PAI-2) in gingival fluid. J Periodont Res 1996;31:271-277
63. Philips M, Juul A-G, Thorsen S, Selmer S, Zeuthen J. Immunological relationship between the fast-acting plasminogen activator inhibitors from plasma, blood, platelets and endothelial cells demonstrated with a monoclonal antibody against an inhibitor from placenta. Thromb Haemostas 1986;55:213-217
64. Gilabert J, Estellés A, Ayuso MJ, et al. Evaluation of plasminogen activators and plasminogen activator inhibitors in plasma and amniotic fluid in pregnancies complicated with intrauterine fetal growth retardation. Gynecol Obstet Invest 1994;38: 156-162
65. Halligan A, Bonnar J, Sheppard B, Darling M, Walshe J. Haemostatic, fibrinolytic and endothelial variables in normal pregnancies and preeclampsia. Br J Obstet Gynaecol 1994;101:488-492
66. Nakashima A, Kobayashi T, Terao T. Fibrinolysis during normal pregnancy and severe pregnancy and severe preeclampsia, relationships between plasma levels of plasminogen activators and inhibitors. Gynecol Obstet Invest 1996;42:95-101
67. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-415
68. Rodgers GM, Taylor RM, Roberts JM. Preeclampsia is associated with a serum factor cytotoxic to human endothelial cells. Am J Obstet Gynecol 1988;159:908-914
69. Nova A, Sibai BM, Barton JR, Mercer BM, Mitchell MD. Maternal plasma level of endothelin is increased in preeclampsia. Am J Obstet Gynecol 1991;165:724-727
70. Lindblom B, Lundberg JM, Junell NO, Nisell H, Norén H, Wolff K. Endothelin - a potent constrictor of small myometrial arteries of term pregnant women. Acta Obstet Gynaecol Scand 1991;70:267-270
71. Taylor RN, Crombleholme WR, Friedman SA, Jones LA, Casal DC, Roberts JM. High plasma cellular fibronectin levels correlate with biochemical and clinical features of preeclampsia but cannot be attributed to hypertension alone. Am J Obstet Gynecol 1991;165:895-901
72. Stubbs TM, Lazarchick J, Horger III EO. Plasma fibronectin levels in preeclampsia: A possible biochemical marker for vascular endothelial damage. Am J Obstet Gynecol 1984;150:885-889